OriGene Logo

Customer Login

Checkout as a new customer

Creating an account has many benefits:

  • See order and shipping status
  • Track order history
  • Check out faster
Create an Account

YAP1 Human shRNA Plasmid Kit (Locus ID 10413)

Be the first to review this product
SKU
TL308332
YAP1 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector, 5µg of each construct provided
  $1,013.00
In Stock*

Frequently Bought Together (4)

TA336916 Mouse Monoclonal YAP1 Antibody (1A12)
100 ul
$620.00
EB200002 Lateral flow testing sticks used for the semi-quantitative detection of the lentiviral p24 protein, 20 tests
20 Tests
$450.00
TR30037 Lenti-vpak packaging kit - packaging plasmids and transfection reagent
10 reactions
$720.00
TF81001 TurboFectin Transfection Reagent (1 mL in 1 vial)
1 ml in 1 vial
$530.00

Other products for "YAP1 or NM_001130145"

Specifications
Specifications
Product Data
Locus ID 10413
Synonyms COB1; YAP; YAP2; YAP65; YKI
Vector pGFP-C-shLenti
E. coli Selection Chloramphenicol (34 ug/ml)
Mammalian Cell Selection Puromycin
Format Lentiviral plasmids
Components YAP1 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector(Gene ID = 10413). 5µg purified plasmid DNA per construct
29-mer scrambled shRNA cassette in pGFP-C-shLenti Vector, TR30021, included for free.
RefSeq NM_001130145, NM_001195044, NM_001195045, NM_001282097, NM_001282098, NM_001282099, NM_001282100, NM_001282101, NM_006106, NM_006106.1, NM_006106.2, NM_006106.3, NM_006106.4, NM_001130145.1, NM_001130145.2, NM_001195045.1, NM_001195044.1, NM_001282098.1, NM_001282097.1, NM_001282099.1, NM_001282100.1, NM_001282101.1, BC038235, BC026212, NM_001195044.2, NM_001282097.2, NM_001130145.3, NM_006106.5, NM_001195045.2
UniProt ID P46937
Summary This gene encodes a downstream nuclear effector of the Hippo signaling pathway which is involved in development, growth, repair, and homeostasis. This gene is known to play a role in the development and progression of multiple cancers as a transcriptional regulator of this signaling pathway and may function as a potential target for cancer treatment. Alternative splicing results in multiple transcript variants encoding different isoforms. provided by RefSeq, Aug 2013
shRNA Design These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact techsupport@origene.com. If you need a special design or shRNA sequence, please utilize our custom shRNA service.
Storage Store at -20°C
Shipping Ambient
Reviews
Write Review
 
 
 
 
 

Be the first to review this product

Please note:
Only reviews with images are eligible for a $20/20€ Amazon gift card.
Reviews without images are eligible for a $10/10€ Amazon gift card.
For more details about the terms and conditions, please visit the promotion page.

Review image
Documents
Resources

file-alt Citations

Concurrent Targeting of Potential Cancer Stem Cells Regulating Pathways Sensitizes Lung Adenocarcinoma to Standard Chemotherapy
Shibata, Ooki, Inokawa et al
Mol. Cancer Ther. (2020)
AI Summary: OriGene contributed to this study by providing the YAP1 shRNA pGFP-C-shLenti Vector (#TL308332), which was used for gene silencing of YAP1 to investigate its role in cancer stem cell regulation and chemotherapy resistance in lung adenocarcinoma.
Snippet: Page 5. 5 determined to be Mycoplasma free. Gene silencing of YAP1 was performed using YAP1 shRNA pGFP-C-shLenti Vector (YAP1-sh) purchased from Origene (Rockville, MD, USA;#TL308332). For YAP1 and STAT3 overexpression, YAP1-inducible
YAP inhibition enhances the differentiation of functional stem cell-derived insulin-producing β cells
Rosado-Olivieri, Anderson, Kenty et al
Nat Commun (2019) 10 (1), 1464 DOI: 10.1038/s41467-019-09404-6
AI Summary: OriGene contributed 29-mer scrambled shRNA and four unique 29-mer YAP shRNAs in pGFP-C-shLenti vectors, which were used to manipulate YAP expression and study its role in the differentiation of stem cell-derived insulin-producing β cells.
Snippet: Lentiviral particles were produced by transfecting 293 T cells (Takara Bio) with the packaging vectors pHDM-vsvg, pHDM-tat, pHDM-rev, and pHDM-gag/pol along with lentiviral backbone vectors using the TransIT-293 transfection reagent (Mirus). The lentiviral vectors used in this study were the following: YAP1(S6A)-pLX304 (addgene #42562), LacZpLX304 (addgene #42560), YAPS6A-pLIX403, GFP-pLIX403, 29-mer scrambled shRNA in pGFP-C-shLenti (Origene), and four unique 29mer YAP shRNAs in pGFP-C-shLenti (Origene)
FigureFigureFigure
Showing 1-2 of 2 papers.
Powered by BizGenius
*Delivery time may vary from web posted schedule. Occasional delays may occur due to unforeseen complexities in the preparation of your product. International customers may expect an additional 1-2 weeks in shipping.

Related Products